Hatteras Venture Partners is a Durham, North Carolina-based venture capital firm founded in 2000. It focuses on seed and early-stage healthcare investing, with particular strength in biopharma, medical devices, diagnostics, and health technology. The firm is deeply embedded in the Research Triangle and broader southeastern US healthcare innovation ecosystem.

The firm has shown meaningful interest in neuroscience and neuro-related healthcare, particularly in areas tied to neurodegeneration, neurocritical care, and translational medicine. Its model is highly operator-oriented, with hands-on support in company building, clinical strategy, hiring, and regulatory planning. Hatteras tends to back companies where strong science can be paired with practical development execution.

Hatteras primarily invests in North America, especially the United States. For neurotech, it is most relevant to clinically oriented companies in medical devices, neurotherapeutics, and translational neuroscience rather than consumer neurotechnology. Its strength is as a healthcare-savvy early-stage partner with real operational depth.